The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · cited 1×
“The ECOG E4599 phase III trial compared the efficacy and safety of paclitaxel and carboplatin and paclitaxel and carboplatin plus 15 mg/kg bevacizumab every 3 weeks in a total of 878 patients with non-squamous cell, stage IIIB–IV NSCLC”
MethodVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“VEGF in association with bFGF, angiopoietin 1 and angio poietin 2 stimulates endothelial proliferation, migration and assembly into vascular networks”
BackgroundKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955 · cited 1×
“The phase III NO16966 trial, which was amended to a 2 × 2 design after bevacizumab was approved, randomly assigned patients to treatment with XELOX (capecitabine and oxaliplatin) or FOLFOX, and then to treatment with bevacizumab or placebo; a total of 1,401 patients were randomized in this second period of the trial”
MethodYang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,463
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,573
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505
Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
Augustin, H. G., Young Koh, G., Thurston, G., & Alitalo, K. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2639 · Cited by 1,465
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J. M., Schrama, J. G., Erdkamp, F. L. G., Vos, A. H., van Groeningen, C. J., Sinnige, H. A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808268 · Cited by 1,341
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,109
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032
Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Ou, S.-S., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9847 · Cited by 899
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850
The PDGF family: four gene products form five dimeric isoforms
Fredriksson, L., Li, H., & Eriksson, U. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.007 · Cited by 838
Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304121.57857.38 · Cited by 801
Cellular abnormalities of blood vessels as targets in cancer
Baluk, P., Hashizume, H., & McDonald, D. M. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.005 · Cited by 781
Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., Douglas, J., Burger, R. A., Armstrong, D., Wenham, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0782 · Cited by 759
Warren, R. S., Yuan, H., Matli, M. R., Gillett, N. A., & Ferrara, N. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117857 · Cited by 694
Sargent, D., Sobrero, A., Grothey, A., O'Connell, M. J., Buyse, M., Andre, T., Zheng, Y., Green, E., Labianca, R., O'Callaghan, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5362 · Cited by 666
Self-citationBiomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
Ohm, J. E., Gabrilovich, D. I., Sempowski, G. D., Kisseleva, E., Parman, K. S., Nadaf, S., & Carbone, D. P. (2003) · Blood · doi:10.1182/blood-2002-07-1956 · Cited by 538
Wedam, S. B., Low, J. A., Yang, S. X., Chow, C. K., Choyke, P., Danforth, D., Hewitt, S. M., Berman, A., Steinberg, S. M., Liewehr, D. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4645 · Cited by 518
Rubenstein, J. L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D. F., & Shuman, M. A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900102 · Cited by 509
Siegel, A. B., Cohen, E. I., Ocean, A., Lehrer, D., Goldenberg, A., Knox, J. J., Chen, H., Clark-Garvey, S., Weinberg, A., Mandeli, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9947 · Cited by 506
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird, A., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., et al. (2000) · PubMed · Cited by 494
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
Oliner, J., Min, H., Leal, J., Yu, D., Rao, S., You, E., Tang, X., Kim, H., Meyer, S., Han, S. J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.030 · Cited by 471
Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E., & Carbone, D. P. (1999) · PubMed · Cited by 459
Yao, J. C., Phan, A., Hoff, P. M., Chen, H. X., Charnsangavej, C., Yeung, S.-C. J., Hess, K., Ng, C., Abbruzzese, J. L., & Ajani, J. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.6374 · Cited by 414
Kunkel, P., Ulbricht, U., Böhlen, P., Brockmann, M. A., Fillbrandt, R., Stavrou, D., Westphal, M., & Lamszus, K. (2001) · PubMed · Cited by 399
Vascular Endothelial Growth Factor Receptor-3 in Lymphangiogenesis in Wound Healing
Paavonen, K., Puolakkainen, P., Jussila, L., Jahkola, T., & Alitalo, K. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65021-3 · Cited by 398
Vascular endothelial growth factor expression in early stage ovarian carcinoma
Paley, P. J., Staskus, K. A., Gebhard, K., Mohanraj, D., Twiggs, L. B., Carson, L. F., & Ramakrishnan, S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970701)80:1<98::aid-cncr13>3.0.co;2-a · Cited by 364
Monk, B. J., Sill, M. W., Burger, R. A., Gray, H. J., Buekers, T. E., & Roman, L. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9043 · Cited by 346
Fan, F., Wey, J. S., McCarty, M. F., Belcheva, A., Liu, W., Bauer, T. W., Somcio, R. J., Wu, Y., Hooper, A., Hicklin, D. J., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208246 · Cited by 342
Thomas, M. B., Morris, J. S., Chadha, R., Iwasaki, M., Kaur, H., Lin, E., Kaseb, A., Glover, K., Davila, M., & Abbruzzese, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3301 · Cited by 334
Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Steinberg, S. M., Jain, L., Annunziata, C. M., Minasian, L., Sarosy, G., Kotz, H. L., Premkumar, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8332 · Cited by 332
Scartozzi, M., Galizia, E., Chiorrini, S., Giampieri, R., Berardi, R., Pierantoni, C., & Cascinu, S. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn637 · Cited by 327
Endogenous angiogenesis inhibitors
FOLKMAN, J. (2004) · APMIS · doi:10.1111/j.1600-0463.2004.apm11207-0809.x · Cited by 321
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F., Novotny, W. F., Hillan, K. J., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji174 · Cited by 319
Feldman, D. R., Baum, M. S., Ginsberg, M. S., Hassoun, H., Flombaum, C. D., Velasco, S., Fischer, P., Ronnen, E., Ishill, N., Patil, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0108 · Cited by 298
Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
Cao, Y. (2009) · Science Signaling · doi:10.1126/scisignal.259re1 · Cited by 289
VEGF receptor protein–tyrosine kinases: Structure and regulation
Roskoski, R. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.121 · Cited by 269
Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Colangelo, L. H., Lopa, S. H., Petrelli, N. J., Goldberg, R. M., Atkins, J. N., Seay, T. E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9220 · Cited by 262
Jayson, G. C., Zweit, J., Jackson, A., Mulatero, C., Julyan, P., Ranson, M., Broughton, L., Wagstaff, J., Hakannson, L., Groenewegen, G., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1484 · Cited by 258
Vascular permeability factor gene expression in normal and neoplastic human ovaries.
Olson, T. A., Mohanraj, D., Carson, L. F., & Ramakrishnan, S. (1994) · PubMed · Cited by 257
Novel anti-angiogenic therapies for malignant gliomas
Norden, A. D., Drappatz, J., & Wen, P. Y. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70260-6 · Cited by 246
Kindler, H. L., Niedzwiecki, D., Hollis, D., Oraefo, E., Schrag, D., Hurwitz, H., McLeod, H. L., Mulcahy, M. F., Schilsky, R. L., & Goldberg, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4508 · Cited by 235
Alfaro, C., Suarez, N., Gonzalez, A., Solano, S., Erro, L., Dubrot, J., Palazon, A., Hervas-Stubbs, S., Gurpide, A., Lopez-Picazo, J. M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604965 · Cited by 214
Miles, D., Chan, A., Romieu, G., Dirix, L. Y., Cortes, J., Pivot, X., Tomczak, P., Taran, T., Harbeck, N., & Steger, G. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.lba1011 · Cited by 213
Experience with irinotecan for the treatment of malignant glioma
Vredenburgh, J. J., Desjardins, A., Reardon, D. A., & Friedman, H. S. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-075 · Cited by 179
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Quant, E. C., Norden, A. D., Drappatz, J., Muzikansky, A., Doherty, L., LaFrankie, D., Ciampa, A., Kesari, S., & Wen, P. Y. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-006 · Cited by 173
What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
HAN, E., & MONK, B. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.01.038 · Cited by 163
Treatment with bevacizumab and irinotecan for recurrent high‐grade glial tumors
Bokstein, F., Shpigel, S., & Blumenthal, D. T. (2008) · Cancer · doi:10.1002/cncr.23401 · Cited by 158
Therapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver
Gray, M. J., Van Buren, G., Dallas, N. A., Xia, L., Wang, X., Yang, A. D., Somcio, R. J., Lin, Y. G., Lim, S., Fan, F., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm279 · Cited by 158
Wu, Y. L., Zhong, Z., Huber, J., Bassi, R., Finnerty, B., Corcoran, E., Li, H., Navarro, E. C., Balderes, P. J., Jimenez, X., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0831 · Cited by 156
Cloughesy, T. F., Prados, M. D., Wen, P. Y., Mikkelsen, T., Abrey, L. E., Schiff, D., Yung, W. K. A., Zheng, M., Dimery, I. W., & Friedman, H. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2010b · Cited by 144
Duda, D. G., Cohen, K. S., Kozin, S. V., Perentes, J. Y., Fukumura, D., Scadden, D. T., & Jain, R. K. (2005) · Blood · doi:10.1182/blood-2005-08-3210 · Cited by 143
Angiopoietin-1 Promotes Tumor Angiogenesis in a Rat Glioma Model
Machein, M. R., Knedla, A., Knoth, R., Shawn, W., Neuschl, E., & Plate, K. H. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63413-x · Cited by 141
Duda, D. G., Cohen, K. S., di Tomaso, E., Au, P., Klein, R. J., Scadden, D. T., Willett, C. G., & Jain, R. K. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2861 · Cited by 134
Wolmark, N., Yothers, G., O'Connell, M. J., Sharif, S., Atkins, J., Seay, T. E., Feherenbacher, L., O’Reilly, S., & Allegra, C. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.lba4 · Cited by 132
The Role of Angiopoietins During Angiogenesis in Gliomas
Reiss, Y., Machein, M. R., & Plate, K. H. (2005) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00116.x · Cited by 128
Pérez, D. G., Suman, V. J., Fitch, T. R., AMATRUDA, T. T., Morton, R. F., Jilani, S. Z., Constantinou, C. L., Egner, J. R., Kottschade, L. A., & Markovic, S. N. (2008) · Cancer · doi:10.1002/cncr.23987 · Cited by 125
Sawada, M., Hadeishi, H., Suzuki, A., & Yasui, N. (2004) · Neurosurgery · doi:10.1227/01.neu.0000129551.64651.74 · Cited by 110
Tozer, G. M., Akerman, S., Cross, N. A., Barber, P. R., Björndahl, M. A., Greco, O., Harris, S., Hill, S. A., Honess, D. J., Ireson, C. R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2011 · Cited by 106
Tew, W. P., Colombo, N., Ray-Coquard, I. L., Oza, A. M., del Campo, J., Scambia, G., & Spriggs, D. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5508 · Cited by 106
Safety of anticoagulation use and bevacizumab in patients with glioma
Nghiemphu, P. L., Green, R. M., Pope, W. B., Lai, A., & Cloughesy, T. F. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-009 · Cited by 93
Küsters, B., de Waal, R. M. W., Wesseling, P., Verrijp, K. C. N., Maass, C., Heerschap, A., Barentsz, J. O., Sweep, F. C. G. J., Ruiter, D. J., & Leenders, W. P. J. (2003) · PubMed · Cited by 92
Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases
Ali, S. A., McHayleh, W. M., Ahmad, A., Sehgal, R., Braffet, M., Rahman, M., Bejjani, G. K., & Friedland, D. (2008) · Journal of neurosurgery · doi:10.3171/jns/2008/109/8/0268 · Cited by 84
Targeting Angiogenesis Driven by Vascular Endothelial Growth Factors Using Antibody-Based Therapies
Grothey, A., & Ellis, L. M. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318178d9de · Cited by 82
Self-citationPathology, genetics and cell biology of hemangioblastomas.
Wizigmann-Voos, S., & Plate, K. H. (1996) · PubMed · Cited by 81
Gerstner, E. R., Sorensen, A. G., Jain, R. K., & Batchelor, T. T. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328318402a · Cited by 72
Hypertension as a surrogate marker for the activity of anti-VEGF agents
Mir, O., Ropert, S., Alexandre, J., & Goldwasser, F. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp206 · Cited by 63
Dallas, N. A., Fan, F., Gray, M. J., Buren, G. V., Lim, S. J., Xia, L., & Ellis, L. M. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9070-2 · Cited by 62
Jayson, G. C., Mulatero, C., Ranson, M., Zweit, J., Jackson, A., Broughton, L., Wagstaff, J., Håkansson, L., Groenewegen, G., Lawrance, J., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.11.021 · Cited by 54
Expression of hypoxia-inducible factor 1a gene affects the outcome in patients with ovarian cancer
Shimogai, R., Kigawa, J., Itamochi, H., Iba, T., Kanamori, Y., Oishi, T., Shimada, M., Sato, S., Kawaguchi, W., Sato, S., et al. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01055.x · Cited by 50
Preliminary Results of the Combination of Bevacizumab and Weekly Paclitaxel in Advanced Melanoma
González‐Cao, M., Viteri, S., Díaz‐Lagares, Á., González, A., Redondo, P., Nieto, Y. L., Espinós, J., Chopitea, A., Ponz‐Sarvisé, M., & Martín‐Algarra, S. (2008) · Oncology · doi:10.1159/000138351 · Cited by 49
Challenges and Pitfalls of Combining Targeted Agents in Phase I Studies
Cannistra, S. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2676 · Cited by 41
Tang, P. A., Cohen, S. J., Bjarnason, G. A., Kollmannsberger, C., Virik, K., MacKenzie, M. J., Brown, J., Wang, L., Chen, A. P., & Moore, M. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4027 · Cited by 37
Cited by
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Papadopoulos, N., Martin, J., Ruan, Q., Rafique, A., Rosconi, M. P., Shi, E., Pyles, E. A., Yancopoulos, G. D., Stahl, N., & Wiegand, S. J. (2012) · Angiogenesis · doi:10.1007/s10456-011-9249-6 · Cited by 1,037
Fang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757
Endothelial von Willebrand factor regulates angiogenesis
Starke, R. D., Ferraro, F., Paschalaki, K. E., Dryden, N. H., McKinnon, T. A. J., Sutton, R. E., Payne, E. M., Haskard, D. O., Hughes, A. D., Cutler, D. F., et al. (2011) · Blood · doi:10.1182/blood-2010-01-264507 · Cited by 512
Angiogenesis Inhibitors: Current Strategies and Future Prospects
Cook, K. M., & Figg, W. D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20075 · Cited by 474
Metadata
- Authors
- Grothey, A., & Galanis, E.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2009-07-28
- Volume
- 6
- Issue
- 9
- Pages
- 507-518
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2011582582
- Cited by
- 356
- References
- 105
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.